Startseite Kongressberichte & Archiv ASCO20 Virtual Scientific Meeting Oral Sessions Breast Cancer II

Breast Cancer — Metastatic

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

1000 KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Javier Cortes, David W. Cescon, Hope S. Rugo, et al.
 
The abstract concludes: 
Pembro combined with several chemo partners showed a statistically significant and clinically meaningful improvement in PFS vs chemo alone in pts with previously untreated locally recurrent inoperable or metastatic TNBC whose tumors expressed PD-L1 (CPS ≥10). Pembro + chemo was generally well tolerated, with no new safety concerns.
 
(Interview zur Studie mit Michael Untch, Berlin-Buch)
 
Watch also the ecancer interview with Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:

 

 

--------------------------------------------------------------------------------------------------------------------------------------------------------

1001 Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).
 
Priyanka Sharma, Eve Rodler, William E. Barlow, et al. 
 
The abstract concludes:
The addition of Vel to cisplatin significantly improved PFS and showed a trend towards improved OS for BRCA-like advanced TNBC. Integral biomarkers used in this study identified a subgroup of BRCAwt TNBC who benefited from addition of PARPi to cisplatin; platinum plus PARPi combination should be explored further in BRCA-like TNBC. Clinical trial information: NCT02595905.

--------------------------------------------------------------------------------------------------------------------------------------------------------

1002 TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
 
Nadine M. Tung, Mark E. Robson, Steffen Ventz, et al. (Interview zur Studie mit Wolfgang Janni, Ulm)
 
The abstract concludes:
In this proof-of-principle study, single-agent olaparib successfully met its primary endpoint in both cohorts. Activity was seen largely in patients with MBC and sBRCA1/2 or gPALB2 mutations but not with ATM or CHEK2 mutations. Clinical trial information: NCT03344965.

---------------------------------------------------------------------------------------------------------------------------------------------------------

1003 Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.
 
Binghe Xu, Min Yan, Fei Ma, et al. 
 
The abstract concludes:
In pts with HER2+ MBC after trastuzumab and chemo, pyrotinib plus capecitabine achieved a significant better PFS than lapatinib plus capecitabine, with manageable toxicity, verifying the phase 2 findings. Clinical trial information: NCT03080805.

--------------------------------------------------------------------------------------------------------------------------------------------------------

1005 Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).
 
Nancy U. Lin, Rashmi Krishna Murthy, Carey K. Anders, Vet al. (Interview zum Thema mit Nadia Harbeck, München)
  
The abstract concludes:
In pts with heavily previously treated HER2+ MBC with BM, TUC in combination with T and C doubled the ORR-IC, reduced risk of IC progression or death by two thirds and reduced risk of death by nearly half. If approved, TUC in combination with T and C has the potential to become a new standard of care in pts with HER2+ MBC with and without BM. Clinical trial information: NCT02614794.
 
See the report in the ASCO DAILY NEWS: 

Triplet Combination Considered New Standard of Care for Patients With HER2-Positive Metastatic Breast Cancer, Brain Metastases

--------------------------------------------------------------------------------------------------------------------------------------------------------

1006 Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.
 
Hope S. Rugo, Florence Lerebours, Eva Ciruelos, et al.  (Interview zum Thema mit Christian Jackisch, Offenbach)
 
The abstract concludes: 
With follow-up still ongoing, BYLieve shows in a large number of pts that ALP + FUL demonstrates clinically meaningful efficacy and manageable toxicity post CDKi tx. Building on findings from SOLAR-1, BYLieve further supports use of ALP + FUL for HR+, HER2–PIK3CA-mut ABC. Clinical trial information: NCT03056755.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:

--------------------------------------------------------------------------------------------------------------------------------------------------------

1007 PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2­ metastatic breast cancer.
 
Antonio Llombart-Cussac, José Manuel Pérez-García, Meritxell Bellet, et al. (Interview zum Thema mit Christian Jackisch, Offenbach)
 
The abstract concludes: 
This study was not able to identify an improvement in PFS for PF over PL in patients with endocrine-sensitive ER[+]/HER2­ MBC. As both arms demonstrated comparable 4 years-OS, PF is a reasonable alternative to PL in this setting. Clinical trial information: NCT02491983.

--------------------------------------------------------------------------------------------------------------------------------------------------------

1008 Randomized trial of a collaborative palliative and oncology care intervention to improve communication about end-of-life care in patients with metastatic breast cancer.
 
Jennifer S. Temel, Beverly Moy, Areej El-Jawahri, et al. (Interview zum Thema mit Volkmar Müller, Hamburg)
 
The abstract concludes: 
This novel collaborative palliative care intervention significantly improved communication and documentation regarding EOL care for women with MBC. Further work is needed to examine the effect of this care model on healthcare utilization at the end of life.

--------------------------------------------------------------------------------------------------------------------------------------------------------

Poster Session:

1055 Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).

Michelino De Laurentiis, Simona Borstnar, Mario Campone, et al.

The abstract concludes:

This analysis confirms the safety and efficacy of RIB+LET in a large, diverse cohort of pts with HR+, HER2– ABC (with no previous ET for ABC), closely resembling real-world clinical practice. Safety and efficacy data were consistent with those observed in the MONALEESA trials, supporting the use of RIB+LET in the first-line setting. NCT02941926. Clinical trial information: NCT02941926.

CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
view slide set

--------------------------------------------------------------------------------------------------------------------------------------------------------

MORE ABSTRACTS:

Clinical Science Symposium
Steps Forward and Lessons Learned: Using Biomarkers to Guide Targeted Therapies in Breast Cancer, The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium supported by the Breast Cancer Research Foundation®.
 
Poster Discussion Session
Breast Cancer—Metastatic
 
Poster Session
Breast Cancer—Metastatic
 
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Breast (Abstracts #LBA2, 501, 506, 1000, 1002, 1007)
Access Content Now